The Khavinson Lineage
The institutional research program that characterized the privileged subclass — the foundation on which the discipline rests.
The Khavinson lineage is the body of biochemical, in-vivo, and clinical research — extending across more than four decades and spanning institutional laboratories across Russia, Ukraine, Italy, South Korea, and the United Kingdom — that established short peptides of two to seven amino acids as a distinct pharmacological category capable of tissue-specific regulation of gene expression.
It is the empirical foundation of endogenic pharmacology. Without it, the discipline could not exist. With it, the discipline inherits a rigorously characterized therapeutic class and a structured mechanism of action.
Four decades, four eras.
- 1960s — 1980s
Origins in institutional biochemistry.
Initial isolation and characterization of short regulatory peptides from animal tissue extracts. Establishment of the foundational hypothesis: that endogenous peptide pools, decreasing with age and organ-specific dysregulation, could be replenished therapeutically through structurally-identical synthetic analogs.
- 1980s — 2000s
Clinical and biochemical validation.
Expansion to in-vivo mammalian study and structured clinical observation. Demonstration of tissue-specific regulatory action, longevity-relevant phenotypic effects, and the consistency of short-peptide bioregulation across multiple organ systems.
- 2000s — 2020s
Mechanistic and molecular characterization.
Resolution of the mechanism: nuclear translocation of short peptides, direct interaction with chromatin and gene-promoter regions, modulation of telomerase activity and gene expression in a tissue-specific manner. Cross-species replication across mouse, rat, primate, and bovine models.
- 2020s — Present
Modern formulation and therapeutic translation.
The trade-named bioregulator portfolio u2014 Telogenixu2122, Thymogenixu2122, Vasogenixu2122, Dermogenixu2122, Cortigenixu2122, Lymphogenixu2122, and Gonadogenixu2122 u2014 extends half-life and enables non-injectable delivery; a patent-pending estate codifies the proprietary modifications.
From institutional research to modern practice.
Endogenic pharmacology is the formalization of the discipline that this lineage made possible. The compounds it characterizes — the short peptide bioregulators, their modifications, their delivery formats, and their indications — are the compounds of the therapeutic class. The mechanism it resolved — tissue-specific gene regulation through nuclear translocation — is the mechanism of the discipline.
The continuity from institutional research to modern clinical practice is direct, traceable, and underwritten by published peer-reviewed evidence.